Patents by Inventor John-Stephen Taylor

John-Stephen Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    Patent number: 9095601
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: August 4, 2015
    Assignee: WASHINGTON UNIVERSITY IN ST. LOUIS
    Inventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
  • CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ("PNAs") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER
    Publication number: 20130230452
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Application
    Filed: December 5, 2012
    Publication date: September 5, 2013
    Applicant: Washington University
    Inventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John Stephen Taylor, Jeffrey L. Tumer, Michael John Welch, Karen L. Wooley
  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    Patent number: 8354093
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: January 15, 2013
    Assignee: Washington University
    Inventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John-Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
  • Nucleic acid triggered catalytic drug and probe release
    Patent number: 7445891
    Abstract: The present invention provides methods and combinations of compositions for the modulation of diseases caused by a subject possessing a disease-specific nucleic acid sequence. Included are methods for the treatment, prevention and/or inhibition of the diseases by administering a combination of a prodrug component, drug and catalytic component such that the drug is catalytically released when contacting the combination to the disease-specific nucleic acid sequence.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: November 4, 2008
    Inventor: John-Stephen Taylor
  • Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ("PNAs") with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
    Publication number: 20060159619
    Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.
    Type: Application
    Filed: October 14, 2005
    Publication date: July 20, 2006
    Inventors: Matthew Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John-Stephen Taylor, Jeffrey Turner, Michael Welch, Karen Wooley
  • Nucleic acid triggered catalytic drug and probe release
    Publication number: 20030060441
    Abstract: The present invention provides methods and combinations of compositions for the modulation of diseases caused by a subject possessing a disease-specific nucleic acid sequence. Included are methods for the treatment, prevention and/or inhibition of the diseases by administering a combination of a prodrug component, drug and catalytic component such that the drug is catalytically released when contacting the combination to the disease-specific nucleic acid sequence.
    Type: Application
    Filed: July 23, 2002
    Publication date: March 27, 2003
    Inventor: John-Stephen Taylor